← All candidates
3 insider filings on record.
3 filings on record.
DNAGinkgo Bioworks Holdings, Inc.
NYSE · Healthcare · $474.41M
$7.01
+3.85% · Sep 14
3 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 1 sell
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what DNA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$474.41M
Float
49.9M
90% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
3.6
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$7.00 avg target
-0.1% vs today · 2 analysts · consensus underperform
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$0.73 act−$0.03
Q1 '26−$1.39 act−$0.05
Q4 '25−$0.77 act+$0.34
Q3 '25−$1.45 act−$0.21
Coverage
Ginkgo Bioworks Q2 Earnings Call HighlightsMarketBeat · 08-08Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call SummaryMoby · 08-07Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab?Insider Monkey · 05-22The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales ForecastsSimply Wall St. · 05-13
The file stays open
3 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice